Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit–Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA

The population with multiple sclerosis receiving treatment in clinical practice differs from that in randomized controlled trials (RCTs). An assessment of the real-world benefit–risk profile of therapies is needed. This analysis used data from the large, noninterventional, observational German study...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziemssen, Tjalf, Lang, Michael, Tackenberg, Björn, Schmidt, Stephan, Albrecht, Holger, Klotz, Luisa, Haas, Judith, Lassek, Christoph, Medin, Jennie, Cornelissen, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794706/
https://www.ncbi.nlm.nih.gov/pubmed/29274026
http://dx.doi.org/10.1007/s13311-017-0595-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794706/
https://www.ncbi.nlm.nih.gov/pubmed/29274026
http://dx.doi.org/10.1007/s13311-017-0595-y

Ejemplares similares